Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"Impressive" HbA1c And Weight Reductions Spur Phase III Plans For Lilly's Dual Incretin Agonist

Executive Summary

Heading into Phase III in 2019 is Lilly's dual agonist of GLP-1 and GIP, which has shown notable therapeutic effects on blood sugar and body weight in type 2 diabetics in a mid-stage clinical study. Meanwhile Lilly/Boehringer Ingelheim's SGLT2 inhibitor, empagliflozin, is being discussed with regulators with regard to its use in type 1 diabetics, an additional indication, following the release of full results from the EASE Phase III program.

You may also be interested in...



Lilly Sees New Product Gains, But Older Drugs Still Limit Growth Potential

Lilly noted strong growth for new products, but gains seen in the fourth quarter included older products with limited potential going forward. That puts even more pressure on the R&D pipeline and the company's revised guidance, but executives were optimistic about future growth drivers.

Lilly’s CVOT Success With Trulicity Causes Bullish Outlook For Diabetes Franchise

Lilly reported strong sales growth for many of its recently launched products, but news of the potentially differentiating REWIND cardiovascular outcomes trial data dominated the pharma’s third quarter earnings call.

Q3 Pharma Earnings Preview: AbbVie, Lilly, AstraZeneca And Bayer

AbbVie faces analysts just a couple weeks after Humira biosimilars hit the market, and with Gilead launching authorized generics of its hepatitis C combos, the TNF franchise is not the only one under attack at AbbVie. Investors are keen to see AstraZeneca start its turnaround to growth, while Lilly is looking to a strong future based on new diabetes data and Bayer braces for a new push in oncology.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132972

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel